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Background: Treatment with steroids covers a wide spectrum of diseases in clinic. However, some users are
suffering from serious side effects of steroid administration, while we enjoy the benefit it brings about.
Osteonecrosis of the femoral head (ONFH) is a troublesome one among them. Recent studies have demonstrated
that lipid metabolism disorder may play a vital role in pathogenesis of ONFH and mutation of the paraoxonase-1
(PON-1) gene may be involved in the occurrence of this disease. However, the relationship between polymorphisms
of PON-1 and ONFH has not been thoroughly studied. The aim of this study was to determine whether PON-1
polymorphisms are associated with steroid-induced ONFH through a cohort study among Chinese Han population.
Methods: This trial applied a case–control scheme to compare the clinical data including PON-1 SNP among 94
patients and 106 control subjects to analyze the association between SNP and risk of steroid-induced ONFH. Time
of Flight Mass Spectrometer is utilized for genotyping and the result was analyzed in multivariate analysis models.
Results: According to polymorphism test of rs662, its SNP was significantly associated with the risk of ONFH in
overdominant analysis model [P value: 0.022; odds ratio (OR): 0.39]. However, genotype frequencies of rs662 of
PON-1 gene between case and control group showed no differences (P > 0.05).
Conclusions: Our data suggest for the first time that SNP (rs662) of the PON-1 gene was associated with the risk of
steroid-induced ONFH. In addition, PAI-1 SNPs may play an important role in pathogenesis of ONFH.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticphatology.diagnomx.eu/
vs/1501829501107336.
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Osteonecrosis of femoral head (ONFH) is a bone disease
that cellular death happens within femoral head owing
to damage of blood supply to the anterior–superior– lat-
eral part of the femoral head [1]. Without effective inter-
vention, most cases will develop collapse of femoral
head and eventually degenerative arthritis of the hip [2].
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stated.to relief or reverse the course of this illness, none of
them is satisfactory to solve this intractable medical con-
dition. Invention of total hip arthroplasty is a milestone
in management of ONFH, however, the patients often
require multiple increasingly difficult surgeries over the
course of a lifetime because the average age at presenta-
tion is very young (about 33 years of age).
Lots of factors as trauma, alcoholism, coagulation de-
fects, hematopathy, certain autoimmune diseases may lead
to osteonecrosis. Beyond that, some treating modalities
also increase the risk of this disease. For example, Bis-
phosphonate contributes to osteonecrosis of jaw (BRONJ)
as well as steroids may induce osteonecrosis in multiple
joints including hip joint [3]. Among ONFH caused bytd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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attention for following reasons: first, there is a growing
trend of its morbidity and some epidemic studies suggests
it has became the leading cause of ONFH; Second, it typ-
ically happens in young patients that is the worst cases to
handle; Last, preventative methods seems effective due to
laboratory trial [4]. From the fact that even receive same
steroid administration regime, not every patient develop
ONFH, it is easy to reach the conclusion that steroid sen-
sitivity are different among people. Hence, it is imperative
for medical community to bring about substantial moves
in prevention. Early perception of susceptible signs in pa-
tients on steroid medication is needed for its prospective
benefits. To address this problem, the etiology and patho-
genesis of ONFH must be thoroughly surveyed to find a
starting point. According to current condition, it is neither
practicable nor necessary to apply preventative modality
on the all patients medicated by steroid, thus screening
for susceptible population seems to be the key point mak-
ing prevention more efficient. With the progress of mo-
lecular biology, increasing number of gene was found to
be associated with certain disease. Further studies com-
bined several functional genes into a model to predict the
occurrence of cancer which make it even closer to clinical
application [5]. Presently, single nucleotide polymorphism
(SNP) arouses vast interests and is believed to be the most
promising direction in this field. In addition to sound
proof favoring SNP is related to disease-susceptibility, it
also possesses a merit called dimorphism which means
each locus comprises of two alleles—it is either this or
that. That leads to low cost and difficulty of detect and
screen which helps SNP to become a hot spot in medical
research. Since its advantages mentioned above, SNP is
widely used in research involving steroid-induced ONFH.
To our knowledge, the specific mechanism of steroid-
induced ONFH is still unclear. Several hypotheses con-
cerning fat embolism, intraosseous hypertension and
venostasis, microvascular impair and osteoporosis are
proposed according to pathological observation and they
are deemed as reliable ones [6-9]. Apparently lipid me-
tabolism abnormality as well as coagulation disorder are
two crucial pathogenic states facilitating this disease. Re-
garding lipid metabolism abnormality, it refers to elevation
of LDL, decrease of HDL and etc. Amount of researches
have demonstrated that hyperlipidimia commonly hap-
pened in steroid-induced ONFH both in laboratory and
clinic [10]. Lipid metabolism is a complicated series of
reactions affected by many substances and paraoxonase
(PON) is one of them which deeply involved its course.
The genetic polymorphism of this enzyme was found to
be linked to hyperlipidemia [5]. Actually, the paraoxo-
nase (PON) multi-gene family consists of at least three
members as PON-1, PON2 and PON3 that map to
7q21.3-22 of chromosome7 [11]. All of the three membersparticipate the proatherogenic oxidative modification of
low-density lipoprotein (LDL) and cell membranes and are
therefore considered to be anti-atherogenic while only
PON-1 is believed to be the major factor in the antioxida-
tive activity of HDL [12,13]. Plymorphyism of the PON-1
gene causes variation of blood levels of PON-1 and its
catalytic efficacy leading to susceptibility to therosclerosis
[14]. PON-1 has two common polymorphisms at codon
192 [A/G: Gln (Q)/Arg (R)] and 55 [T/A: Leu(L)/Met
(M)]. It has been proven that the variation and enzyme ac-
tivity has a cause and effect relationship [15]. In certain
populations, elevated enzyme activity gives birth to higher
HDL level [16]. Recent researches mainly focus on PON
192 and 55 polymorphisms, several trials found that they
were associated with risk of ischemic vascular events as
stroke and coronary heart disease [17]. One study also
showed that PON-1 192QQ genotype increased risk for
steroid-induced ONFH [18]. On the basis of these find-
ings, we hypothesized that there might be a possible rela-
tionship between SNP of PON-1 and steroid-induced
ONFH. In order to validate this hypothesis, we performed




This study was approved by the ethic committee of two
hospital involved—namely Wangjing Hospital, China
Academy of Chinese Medical Sciences and Hematology
& Blood Diseases Hospital,Chinese Academy of Medical
Sciences. And informed consent of all individuals en-
rolled in the study were obtained after they were full in-
formed what they were engaging in.
A total of 94 patients with steroid-induced ONFH (case
group, 40 men, 54 women; mean age: 40.22 ± 14.78 years)
and 106 patients who did not develop steroid-induced
ONFH (reference group, 64 men, 42 women; mean age:
43.09 ± 18.36 years) following steroid administration were
consecutively enrolled at Wangjing Hospital and Institute
of Hematology & Blood Diseases Hospital of China Acad-
emy of Chinese Medical Sciences from March 2011 to
December 2012. All the subjects are from 14 provinces in
China, including Hebei (n = 41), Beijing (n = 32), Tianjin
(n = 27), Shandong (n = 21), Henan (n = 18), Liaoning
(n = 14), Jilin (n = 11), Shanxi (n = 10), Heilongjiang (n =
10), Neimenggu (n = 8), Guizhou (n = 3), Ningxia (n = 2),
Shanxi (n = 2) and Qinghai (n = 1). Steroid-induced ONFH
was defined by a history of a mean daily dose of ≥ 16.6 mg
or highest daily dose of 80 mg of predinosolone equivalent
within 1 year prior to the development of symptoms or
radiological diagnosis in asymptomatic cases (Oinuma et al.
2001; Koo et al. 2002; Mont et al. 2006) [19-21]. Underlying
diseases in steroid-induced ONFH were hematologic dis-
eases (n = 23 patients), dermatogic diseases (n = 9 patients),
Table 1 Clinical information
Factor Steroid-induced ONFH
Cases (N = 94)
Non steroid-induced
ONFH Cases (N = 106)
P
Gender Male 40 64 0.02
Female 54 42
Age 40.22 ± 14.78 43.09 ± 18.36 0.23
Body mass index (BMI, Kg/m2) 23.01 ± 3.00 24.36 ± 2.42 < 0.001
Affected sides Unilateral 15 –
Bilateral 79 –
Steroid treatment Oral medication 74 89 0.06
Intravenous injection 36 71
Steroid dose Large (> 400 mg/d) 34 60 0.12
Middle (> 100 mg/d & < 400 mg/d) 52 40
Small (< 100 mg/d 8 6
Treatment duration (days) 1140.34 ± 2014.037 2631.54 ± 8610.278 0.10
Underlying diseases (reason for steroid) Hematologic diseases 23 106 < 0.001
Dermatogic diseases 9 0
Renal diseases 9 0
Ophthalmopathy 6 0
Respiratory disease 5 0
others 42 0
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tients), diseases of respiratory system (n = 5 patients), and
others (n = 42 patients). Patients with a demonstrable his-
tory of direct trauma or with possible combined causes
were excluded. The clinical characteristics of patients in
case and reference groups were summarized in Table 1.
Candidate PON-1 single nucleotide polymorphism
(SNP) selection
A well-studied functional SNPs in the PON-1 gene, rs662
(−844 G/A, in the promoter) was selected in the list of
genotyping in this study for its important functions in
regulating PON-1 expression and in the development of
ONFH. As the results of our literature retrieval from
PubMed database (http://www.ncbi.nlm.nih.gov/pubmed),
a study showed for the first time that rs662 was essential
SNP involved in the regulation of PON-1 gene expression
in ONFH using a Greek population [18]. According to
their analysis, they confirmed the risk effects of rs662 in
the non-traumatic ONFH. In the current study, the rela-
tionship between rs662 SNP and the development of
steroid-induced ONFH were investigated using a large co-
hort of Chinese population.Table 2 Polymerase chain reaction primers of SNP
SNP PCR primer Sequence
Rs662 1st-Primer ACGTTGGATGGATCACTATTTTCTTGA
2nd-primer ACGTTGGATGTAGACAACATACGACCADNA isolation
Genomic DNA was extracted from 2 mL whole-blood
samples using the QIAamp DNA Blood Mini kit (Qiagen,
Inc., Valencia, CA) following the manufacturer’s protocol.
After dilution to 20 g/μL, DNA was distributed in 96-well
plates and stored at −80.
PON-1 SNP genotyping
SNP genotyping was performed on the SEQUENOM
MassARRAY® Analyzer 4 (Sequenom, Inc., San Diego,
CA, USA) using genomic DNA in a single multiplex
reaction. Primers for polymerase chain reaction (PCR)
amplification and single base extension were designed by
Sequenom Assay Design 3.1 software (Sequenom, San
Diego, CA, USA) according to the manufacturer’s in-
structions (Table 2). For quality control, genotyping was
performed without knowledge of the case/control status
of the subjects, and a random sample of 5% of cases and
controls was genotyped again by different researchers.
The reproducibility was 100%. The genotyping success
rate was over 95%. In this section, researchers were blind
to group information of samples they deal with to avoid
selection bias.Extension primer Sequence
CCC 1st-Primer TGTTCTTGACCCCTACTTACA
CGC 2nd-primer TGTTCTTGACCCCTACTTACG
Table 3 Exact test of rs662 for Hardy-Weinberg
equilibrium (n = 195)
N11 N12 N22 N1 N2 P-value
All subjects 68 97 30 233 157 0.77
co.ca = 0 30 57 15 117 87 0.22
co.ca = 1 38 40 15 116 70 0.51
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Whether individual variants were in Hardy–Weinberg
equilibrium was determined by Chi-square tests. Chi-
square tests were adopted to assess differences in geno-
type and allele frequency between case group and control
group. Beyond that, statistical significance was judged by
the p values obtained from the logistical regression ana-
lysis, controlling for age, gender, body mass index (BMI),
concurrent disease, steroid dose and duration of steroid
administration as covariates with four alternative models
(codominant, dominant, recessive and overdominant). All
analyses were two-tailed and a p value less than 0.05 were
considered to be statistically significant. Statistical analyses
were performed by using SAS 9.1 (SAS Institute Inc. Cary,
NC, USA) as well as SPSS 12.0 (SPSS Inc, IL, USA).
Results
Patient characteristics
Analysis showed that age, steroid treatment, steroid dose,
and duration of steroid treatment between case group and
control group was similar (all P > 0.05). However, two
groups were obviously different from each other in gender,
(P = 0.02), BMI (P < 0.001) and concurrent disease (P <
0.01). More Male patient suffered from ONFH among these
steroid users while more patients with relative less BMI de-
veloped ONFH.
Polymorphism of rs662 was associated with the risk of
steroid-induced ONFH
The genotype frequency of rs662 polymorphism was in
accordance with Hardy-Weinberg equilibrium in bothTable 4 Association between rs662 SNPs and the risk of stero
Model Genotype co.ca = 0 co.ca = 1
Codominant G/G 23 (27.1%) 27 (38.6%)
A/G 49 (57.6%) 30 (42.9%)
A/A 13 (15.3%) 13 (18.6%)
Dominant G/G 23 (27.1%) 27 (38.6%)
A/G-A/A 62 (72.9%) 43 (61.4%)
Recessive G/G-A/G 72 (84.7%) 57 (81.4%)
A/A 13 (15.3%) 13 (18.6%)
Overdominant G/G-A/A 36 (42.4%) 40 (57.1%)
A/G 49 (57.6%) 30 (42.9%)
Log-additive — — —case and control groups (Table 3). The P values of poly-
morphism were analyzed by logistic analysis with respect
to a comparison between steroid-induced patients and
the controls.
As shown in Table 4, the rs662 allele and genotype fre-
quencies showed a significantly higher risk factor in ONFH
patients compared with those in controls with P values
0.022 (OR; 0.39, 95% CI; 0.17-0.89) in the overdominant
model. Though the P value of rs662 genotype frequency in
the condominant model was slightly greater than 0.05 (P =
0.072), it showed the tendency of weak association with
the risk of ONFH development. No differences in the fre-
quencies of the allele and genotypes were seen in patients
and the controls in the case rs662 polymorphisms.
Discussion
Although collapse of femoral head is the distinctive feature
in radiography which is easy to be identified, it commonly
happens in the middle stage. Before that, bone marrow
edema, cystic degeneration, bone density loss and other
manifestations are all nonspecific signs. Then, the forth-
coming subchondral fracture (crescent signs) and calcifica-
tion zone is reasonable proof for diagnosis but they also
mean that the best time for treatment has been past. In
addition, pain-the major symptom in early stage, may oc-
curs in lower back, hip or even knees that makes it even
more difficult to be diagnosed. Histopathological study re-
veals that, steroid-induced ONFH suffered diffusive lesions
in whole femoral head. Due to the inhibiting effects of
steroid on osteoblast the bone repairing course becomes
much slower. Furthermore, insufficient blood flow caused
by steroid further compromise the repairing process.
Consequently, the collapse may develop much faster.
Take into account these unfavorable characteristics of
steroid-induced ONFH, predicting factors of this dis-
ease are needed for prevention and early intervention.
This study was conducted to identify a genetic factor
contributing to onset of steroid-induced ONFH. The re-
sult indicated that, under the overdominant model, A/Gid-induced ONFH
OR (95% CI) P-value AIC BIC
1.00 0.072 189.5 235.1
0.38 (0.14-1.01)
0.95 (0.29-3.14)
1.00 0.13 190.4 233
0.49 (0.20-1.24)
1.00 0.23 191.3 233.9
1.83 (0.67-5.02)
1.00 0.022 187.5 230.1
0.39 (0.17-0.89)
0.92 (0.51-1.66) 0.78 192.7 235.3
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than A/A and G/G carriers among patients managed by
steroid, suggesting that A/G carriers may have a lower
sensitivity to GC than A/A and G/G carriers. In a word,
our data suggest for the first time that SNP (rs662) of
the PON-1 gene was associated with the risk of steroid-
induced ONFH.
As mentioned above, accumulating studies were per-
formed to investigate the relationship between SNP of
rs662 (Q192R) and other vascular ischemic diseases. How-
ever, their results were not consistent. Two cohort studies
in Britain which found no evidence that PON-1 Q192R
polymorphism is associated with CHD risk in Caucasian
women or men [22,23]. However, the investigation in Thai
population turned out to be opposite—a firm association
between polymorphism of Q192R and CHD was observed
[24]. For stroke, a study in Chinese population showed
that Q192R polymorphism (the R allele and RR genotype)
was associated with an increased risk of ischemic stroke
[17]. On the contrary, a research in Greece indicated that
no links between Q192R and stroke was detected [25,26].
The demographic factors as ethic background may con-
tribute to this paradox.
There are several highlights in the current study as fol-
lowing: first, PON-1 polymorphism has been a hot issue,
however, very few researches was designed to investigate
its relationship with ONFH; Second, differences in PON-1
activity, concentration and genotype distribution have
long been known to occur between different populations
and geographical regions throughout the world. Accord-
ingly, this is deemed as one of the major controversies
between studies concerning relationship between PON-1
polymorphism and other diseases. In this study, all partici-
pants were confined as Han Chinese lived in north areas
of the Yellow River that is designed to avoid deviation
caused by ethical and geographical factors. Last but not
the least, unlike some other studies that using healthy
people as controls, this research recruit steroid users with-
out developing ONFH as reference group. This scheme is
of an obvious advantage that it excludes the influence of
steroid—a pathogenic factor on subjects of different groups.
Consequently, it increases the reliability of the result.
However, there are several limitations in this study.
First, the sample size is relative small, which may influence
the reliability of our results because the heterogeneity of
concurrent diseases of subjects may lead to selection bias
of the result. Second, it is still unknown that by which way
it facilitates ONFH. Though PON-1 polymorphism is
linked to Atherosclerosis, it could not explain its relation-
ship with steroid-induced ONFH. Not like the chronic
course of the former one, the latter one is a medical con-
dition happened much faster. Therefore, the exact mecha-
nisms by which the polymorphisms of the PON-1 gene
are involved in the development of steroid-induced ONFHrequire further investigations. And its result may provoke
more deep understanding on safe protocol of steroid
administration.
In conclusion, our data provide the convincing evi-
dence for the first time that rs662 SNP of PON-1 may
be associated with the risk of steroid-induced ONFH,
suggesting that the genetic variations of this gene may
play an important role in the disease development. Fol-
lowing study is needed for its prospecting result.
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